Option Care Health reached a fresh 12-month peak after Morgan Stanley increased its price target from $35.00 to $38.00 and maintained an overweight rating. The stock traded intraday volume of approximately 2.55 million shares, eclipsing its 30-day average of 2.1 million. This marked its highest close since February of last year, underscoring renewed investor confidence following the analyst action.

Management raised full-year 2025 earnings per share guidance to a range of 1.72–1.76, above the consensus estimate of 1.64, and set Q4 EPS guidance above street forecasts. Preliminary net revenue for Q4 is expected between $1.46 billion and $1.47 billion, up from $1.35 billion in the prior-year quarter. Analysts from Deutsche Bank and Citizens/JMP have also boosted targets to $36.00 and $38.00 respectively, contributing to a consensus rating of Moderate Buy and an average price target of $37.17.

Director Harry M. Jansen Kraemer, Jr. purchased 38,000 shares at an average cost of $25.98 per share on November 3, increasing his ownership by 10.12% to 413,390 shares valued at approximately $10.74 million. Insider holdings represent 0.64% of outstanding shares, indicating top-level conviction in projected profitability and execution of the merger with BioScrip completed in early 2021.

Institutional investors control 98.05% of shares, with recent stakes established by USA Financial Formulas, Cornerstone Planning Group, Advisory Services Network and others. The company’s market capitalization stands near $5.64 billion, with a price-to-earnings ratio of 28.18, a PEG of 2.17 and a beta of 0.80. Its balance sheet shows a debt-to-equity ratio of 0.85, a current ratio of 1.56 and a quick ratio of 1.05, supporting liquidity and moderate leverage levels.